Loti Labs: Public Sources and Testing Claims
Loti Labs has an accessible public COA archive and published transaction policies. Those are useful source records, while the laboratory findings, offered lot and actual fulfillment still need their own verification.
What the public COA archive contains
The archive checked October 27, 2026 indexed 108 entries with product, batch, date and testing metadata. It says testing laboratories are checked where available. This is a seller-maintained directory, not our authentication of each report or confirmation that a posted sample represents stock being offered now.
The actual processing and returns policy
The policy describes weekday processing before 1 p.m. Eastern, free US shipping above $99 and estimated transit ranges. It expressly treats delivery times as estimates. It describes domestic shipping and conditional returns within 30 days for unused, unopened goods; do not turn those terms into guaranteed delivery or an unconditional refund.
Contact information and research restrictions
Contact channels list business-hours support; we did not contact staff or measure response quality. The terms restrict sales to qualified researchers aged 21 or older. This does not establish clinical dispensing or suitability for patients.
What an independent assessment still needs
Match the offered material and lot to the original laboratory report, including issuer, date, methods and results. Purity, amount, identity, sterility and endotoxin results answer different questions. A posted report is useful documentation; authenticity, sampling and coverage of the actual lot still matter.
Research sellers and clinical treatment
A research-use restriction does not establish human-use safety or create a clinical prescription pathway. FDA’s GLP-1 notice warns about research-labeled products sold for human use. This general context is not a vendor-specific enforcement finding. No patient experience, clean regulatory record or representative customer-satisfaction rating is established here. The distinction between a research compound and a medicine is covered in our guide to FDA approval.
Related reading
- Loti Labs published statements
- Loti Labs COA archive
- FDA analytical validation guidance
- Loti Labs shipping policy
- Loti Labs contact page
- Loti Labs return terms
- Loti Labs research-use terms
- FDA research-label warning
- FDA compounding explanation
- Best Peptide Vendors 2026: Comprehensive Comparison
- How to Buy Peptides Safely: Vendor Selection Guide
- BPC-157: Complete Research Guide and Vendor Comparison
- FDA
- catalog
- product
Frequently Asked Questions
The site publishes a storefront, terms and an extensive COA directory. Those observations do not independently authenticate the legal entity, every lot or transaction performance.
The public archive provides batch and analytical documentation to examine. No individual report or representative product-quality conclusion was independently authenticated here.
The seller maintains a public COA archive with laboratory metadata and says laboratories are checked where available. Match the actual lot and authenticate the original issuer.
A directory entry is not proof of current stock. Confirm the exact current research listing, material and lot; no clinical-use menu is established.
No complete same-scope competitor price survey was performed. Compare written total costs for an identified material and amount.
The policy gives processing and transit estimates, not observed performance. No test shipment or representative delivery record was reviewed.
No comprehensive court or enforcement-history finding is established. FDA’s general GLP-1 notice is not a Loti-specific allegation or clean-record certification.
A larger catalog or company does not establish better lot quality. Compare authenticated documentation and transaction terms, while keeping clinical treatment with licensed care.